{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-034338","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.424537+00:00","generated_at":"2026-05-30T02:04:07.898835+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Reviva: 108 patients complete 1-year brilaroxazine OLE; topline data expected Dec 2024","bullets":["108 patients completed 12-month treatment; over 250 completed 6 months in the OLE study.","Long-term safety data from 100 patients with 12 months treatment now available for planned NDA submission.","Brilaroxazine continues to be generally well tolerated in acute and stable schizophrenia patients.","Topline 12-month long-term safety and efficacy data expected in December 2024.","OLE study (RECOVER) completion anticipated in Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-034338","json":"https://secwatch.observer/filing/0001437749-24-034338.json","markdown":"https://secwatch.observer/filing/0001437749-24-034338.md","text":"https://secwatch.observer/filing/0001437749-24-034338.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924034338/0001437749-24-034338-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924034338/rvph20241111_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:04:07.898835+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}